

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Doron Marco	01/15/2008
Shimon Eckhouse	01/15/2008
RECEIVING PARTY DATA	
Name:	Tulip Biotechnology Ltd.
Street Address:	20/3 David Avidan St.
City:	Tel Aviv
State/Country:	ISRAEL
Postal Code:	69626
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11788574
CORRESPONDENCE DATA	
Fax Number:	(650)858-2131
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650-302-6286
Email:	tom@etwheelocklaw.com
Correspondent Name:	E. Thomas Wheelock
Address Line 1:	P.O. Box 61168
Address Line 4:	Palo Alto, CALIFORNIA 94306
ATTORNEY DOCKET NUMBER:	35101-20001.20
NAME OF SUBMITTER:	E. Thomas Wheelock
Total Attachments: 2 source=351012000120assignment#page1.tif source=351012000120assignment#page2.tif	

OP \$40.00 11788574

ASSIGNMENT

THIS ASSIGNMENT (the "Assignment") is by **Doron MARCO and Shimon ECKHOUSE**, (the "Assignors"), individuals having addresses respectively at 20/3 David Avidan St., Tel Aviv 69626, Israel and 52 Hag St., Haifa 34820, Israel and is to **TULIP BIOTECHNOLOGY LTD.**, (the "Assignee"), a corporation organized under laws of Israel, and having an address at 20/3 David Avidan St., Tel Aviv 69626, Israel.

The Assignors have made certain inventions described in an application for patent, in a provisional application for patent, or in an issued patent in the United States specified below and wish to assign to the Assignee all rights, title, and interest in the specified application, provisional application, or patent, in the resulting U.S. and foreign patents and patent applications, and in the underlying inventions.

The application for patent or provisional application for patent, in either case having the title: **BIOERODIBLE SELF-DEPLOYABLE INTRAGASTRIC IMPLANTS** is filed with this Assignment, or was filed on April 19, 2007 and has the Serial Number 11/788,574.

The issued patent has the patent number _____ and was issued on _____.

TULIP BIOTECHNOLOGY LTD. wishes to acquire the entire right, title, and interest in (a) the specified issued patent, application for patent, or provisional application for patent, (b) in all U.S. and foreign patent applications and patents based on the specified application for patent or provisional application for patent, and (c) in the underlying inventions.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is acknowledged, the Assignors affirm that they have assigned and by this Assignment, do assign to TULIP BIOTECHNOLOGY LTD., their entire right, title and interest (a) in the above-specified application for patent, provisional application for patent, or patent, (b) in all U.S. and foreign patent applications and patents based on the specified application for patent or provisional application for patent, (c) in the underlying inventions, (d) in any and all divisions, continuations, and continuations-in-part of the specified application for patent, (e) in all reissues or extensions of the specified patent or of patents based on the specified application for patent or provisional application for patent, and (f) all rights under the International Convention for the Protection of Industrial Property

The Assignors also covenant to TULIP BIOTECHNOLOGY LTD., that, at the date of this Assignment, (a) Doron Marco and Shimon Eckhouse are joint lawful owners of the entire right, title, and interest in the in the above-specified application for patent, provisional application for patent, or patent, and in the underlying inventions, (b) that right, title, and interest is unencumbered, and (c) that they have the authority to convey that right, title, and interest in the manner provided in this Assignment.

Assignors agree that if this Assignment assigns a specified patent, they further assign to TULIP BIOTECHNOLOGY LTD. the right to sue for and to collect damages for infringement occurring prior to the date of this Assignment.

Assignors agree that if this Assignment assigns a specified application for patent or provisional application for patent, the serial number for which is provided by the United States Patent and Trademark Office after the date of this Assignment, they agree that TULIP BIOTECHNOLOGY LTD. may enter such serial number in the space provided above without affecting the assignments made herein.

Assignors further agree to provide assistance to TULIP BIOTECHNOLOGY LTD., its successors, legal representatives, and assigns, by signing all papers and documents, taking all lawful oaths, and doing all acts necessary or required for :

- a) procurement, maintenance, enforcement, and defense of the above-specified application for patent, provisional application for patent, or patent and of the other patents and patent applications assigned herein, in any country;
- b) proceedings in connection with the underlying invention assigned herein, in any country;
- c) interference proceedings in connection with the above-specified application for patent, provisional application for patent, or patent,
- d) proceedings in connection with prosecution of any division, continuation, or continuation-in-part assigned herein, and
- e) proceedings in connection with the reissue, reexamination, or extension of any patent assigned herein,

where TULIP BIOTECHNOLOGY LTD.'s counsel or the counsel representing TULIP BIOTECHNOLOGY LTD.'s successors, legal representatives, or assigns, advises of the desirability or necessity of doing so. TULIP BIOTECHNOLOGY LTD. agrees to reimburse or to pay the Assignors' costs and expenses in providing such assistance. Such costs will include reimbursement of the Assignor lost normal compensation.

Assignors request the Director of the U.S. Patent and Trademark Office issue all U.S. patents assigned under this Assignment to TULIP BIOTECHNOLOGY LTD.

15 January 2008
Date 
Doron MARCO

15 January 2008
Date 
Shimon ECKHOUSE

TULIP BIOTECHNOLOGY LTD. accepts the assignment provided above.

15 January 2008
Date 
Allon Reiter, CEO